8Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease.Gastroenterology, 2002, 123: 1705-1725.
9Vong S, Bell BP. Chronic liver disease mortality in the United States, 1990-1998. Hepatology, 2004, 39: 476-483.
10Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med,2000, 132: 112-117.
2Clark JM.The epidemiology of nonalcoholic fatty liver disease in adults[J].J Clin Gastroenterol,2006,40(3 Suppl 1):S5-S10.
3Barshop NJ,Sirlin CB,Schwimmer JB,et al. Review article:epidemiol ogy,pathogenesis and potential treatments of paediatric nonalcoholic fatty liver disease[J]. Aliment Pharmacol Ther,2008,28(1):13-24.
4Medina J,Fernandez Salazar LI,Garcia Buey L,et al.Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis[J]. Diabetes Care,2004,27(9):2057-2066.
5ho M,Suzuki J,Sasaki M,et al.Development of nonalcoholic steato- hepatitis model through combination of high-fat diet and tetracycline with morbid obesity in mice[J].Hepatol Res,2006,34(2):92-98.
6Liou I,Kowdley KV.Natural history of nonalcoholic steatohepatitis[J]. J Clin Gastroenterol,2006,40(3 Suppl 1):11-16.
7Rajnarayana K,Reddy MS,Vidyasagar J, et al. Study on theinfluence of silymarin pretreatment on metabolism and disposition of metronidazole[J].Arzneimittelforschung,200d,54(2): 109-113.
8Polyak SJ,Morishima C,Lohmann V,et al.Identification of hepatopmtective flavonolignans from silymarln[J].Proc Natl Acad Sei USA,2010,107(13):5995-5999.
9Feh6r J,Lengyel G.Silymarin in the treatment of chronic liver diseases:past and future[J].Orv Hetil,2008,149(51):2413-2418.
